Research ArticleRheumatoid Arthritis
Open Access
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C. Radominski, Joan T. Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller and Janet E. Pope
The Journal of Rheumatology April 2018, 45 (4) 456-464; DOI: https://doi.org/10.3899/jrheum.161539
Alan Kivitz
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California,
USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California,
Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla,
Spain; Universidade Federal do Paraná, Curitiba,
Brazil; Roche Pharmaceuticals, Welwyn Garden City, London,
UK; St. Joseph’s Health Centre, Western University, London, Ontario,
Canada.
Ewa Olech
Michael A. Borofsky
Beatriz Zazueta
Federico Navarro-Sarabia
Sebastião C. Radominski
Joan T. Merrill
César Pacheco-Tena
Jinglan Pei
Clare Nasmyth-Miller
REFERENCES
- 1.↵
- Emery P,
- Keystone E,
- Tony HP,
- Cantagrel A,
- van Vollenhoven R,
- Sanchez A,
- et al.
- 2.↵
- Genovese MC,
- McKay JD,
- Nasonov EL,
- Mysler EF,
- da Silva NA,
- Alecock E,
- et al.
- 3.↵
- Jones G,
- Sebba A,
- Gu J,
- Lowenstein MB,
- Calvo A,
- Gomez-Reino JJ,
- et al.
- 4.↵
- 5.↵
- Burmester GR,
- Rubbert-Roth A,
- Cantagrel A,
- Hall S,
- Leszczynski P,
- Feldman D,
- et al.
- 6.↵
- 7.↵
- 8.↵
- Burmester GR,
- Rubbert-Roth A,
- Cantagrel A,
- Hall S,
- Leszczynski P,
- Feldman D,
- et al.
- 9.↵
- Ogata A,
- Amano K,
- Dobashi H,
- Inoo M,
- Ishii T,
- Kasama T,
- et al.
- 10.↵
- 11.↵
- Stubenrauch K,
- Wessels U,
- Birnboeck H,
- Ramirez F,
- Jahreis A,
- Schleypen J
- 12.↵
- Genovese MC,
- Rubbert-Roth A,
- Smolen JS,
- Kremer J,
- Khraishi M,
- Gomez-Reino J,
- et al.
- 13.↵
In this issue
The Journal of Rheumatology
Vol. 45, Issue 4
1 Apr 2018
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C. Radominski, Joan T. Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, Janet E. Pope
The Journal of Rheumatology Apr 2018, 45 (4) 456-464; DOI: 10.3899/jrheum.161539
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C. Radominski, Joan T. Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, Janet E. Pope
The Journal of Rheumatology Apr 2018, 45 (4) 456-464; DOI: 10.3899/jrheum.161539